Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.30 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535084 | 0.87 | KDM1A (0.39) | KDM1AOPRK1 | |
| SCHEMBL20534937 | 0.86 | DAGLB (0.32) | KDM1ADAGLBDAGLA | |
| SCHEMBL20535067 | 0.80 | KDM4E (0.37) | OPRK1DAGLBDAGLA | |
| SCHEMBL20535916 | 0.77 | NR1D1 (0.35) | OPRK1 | |
| SCHEMBL23211673 | 0.77 | POLB (0.35) | — | |
| SCHEMBL21216118 | 0.76 | KDM1A (0.46) | KDM1ADAGLA | |
| SCHEMBL21216287 | 0.75 | JAK2 (0.34) | — | |
| SCHEMBL21216115 | 0.74 | SIGMAR1 (0.42) | — | |
| SCHEMBL21216231 | 0.73 | JAK2 (0.44) | KDM1A | |
| SCHEMBL21216112 | 0.73 | JAK2 (0.44) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| EP-3609866-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | Evonetix Ltd (GB) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018189546-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | EVONETIX LTD (GB) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | KDM1A 1656/4885OPRK1 2808/4885CNR2 3935/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | KDM1A 1656/4885OPRK1 2808/4885CNR2 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.